Catch me if you can: how AML and its niche escape immunotherapy

In spite of the remarkable progress in basic and preclinical studies of acute myeloid leukemia (AML), the five-year survival rate of AML patients remains poor, highlighting the urgent need for novel and synergistic therapies. Over the past decade, increased attention has been focused on identifying...

Descripción completa

Detalles Bibliográficos
Autores principales: Tettamanti, Sarah, Pievani, Alice, Biondi, Andrea, Dotti, Gianpietro, Serafini, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727297/
https://www.ncbi.nlm.nih.gov/pubmed/34302116
http://dx.doi.org/10.1038/s41375-021-01350-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727297/
https://www.ncbi.nlm.nih.gov/pubmed/34302116
http://dx.doi.org/10.1038/s41375-021-01350-x

Ejemplares similares